Anika Therapeutics (ANIK) vs K2 Capital Acquisition (KTWO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Anika Therapeutics is the larger company by market cap ($261.4 million vs $201.8 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIK | KTWO |
|---|---|---|
| Share price | $19.53 | $10.07 |
| Market cap | $261.37M | $201.81M |
| 1-day change | +2.14% | -0.20% |
| YTD return | +103.23% | — |
| 1-year return | +114.85% | — |
| 5-year return | -53.12% | — |
| Forward P/E | 20.56 | — |
| EPS (TTM) | $-0.23 | — |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.88 | $10.10 |
| 52-week low | $8.67 | $9.84 |
| Distance from 52-week high | -14.64% | -0.30% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +17.77% | — |
| Average volume | 98.17K | 29.51K |
| Shares outstanding | 13.38M | 14.13M |
| Employees | 235 | — |
| Sector | Healthcare | Financial Services |
| Industry | Drug Manufacturers - Specialty & Generic | Shell Companies |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Anika Therapeutics in Healthcare and K2 Capital Acquisition in Financial Services.
About Anika Therapeutics
ANIK stock →Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation.
Healthcare · Drug Manufacturers - Specialty & Generic · 235 employees
About K2 Capital Acquisition
KTWO stock →K2 Capital Acquisition Corporation does not have significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities in the physical AI or energy transition sectors.
Financial Services · Shell Companies
ANIK vs KTWO FAQ
Which is bigger, Anika Therapeutics or K2 Capital Acquisition?
Anika Therapeutics (ANIK) is larger, with a market capitalization of $261.37M compared with $201.81M for K2 Capital Acquisition (KTWO).
Are Anika Therapeutics and K2 Capital Acquisition in the same industry?
No. Anika Therapeutics is in the Healthcare sector, while K2 Capital Acquisition is in Financial Services.